These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15164042)

  • 1. Automata make antisense.
    Condon A
    Nature; 2004 May; 429(6990):351-2. PubMed ID: 15164042
    [No Abstract]   [Full Text] [Related]  

  • 2. An autonomous molecular computer for logical control of gene expression.
    Benenson Y; Gil B; Ben-Dor U; Adar R; Shapiro E
    Nature; 2004 May; 429(6990):423-9. PubMed ID: 15116117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase.
    Zemskova M; Wechter W; Bashkirova S; Chen CS; Reiter R; Lilly MB
    Biochem Pharmacol; 2006 Nov; 72(10):1257-67. PubMed ID: 16949054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The "antisense" strategy: a new approach in the development of antineoplastic substances and gene therapy].
    Hélène C
    J Pharm Belg; 1997; 52(2):79-85. PubMed ID: 9296958
    [No Abstract]   [Full Text] [Related]  

  • 6. Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.
    Skogseth H; Follestad T; Larsson E; Halgunset J
    APMIS; 2006 May; 114(5):364-71. PubMed ID: 16725013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Up-regulates the expression of maspin gene in prostate cancer cell line LNCaP].
    Shi P; Chen WW; Hu XY; Yu CX; Zhang PJ; Jiang AL; Zhang JY
    Yao Xue Xue Bao; 2006 Dec; 41(12):1152-6. PubMed ID: 17290611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomy.
    van der Poel HG
    Eur Urol; 2008 Feb; 53(2):344. PubMed ID: 17448596
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomy.
    Lin DW
    Eur Urol; 2008 Feb; 53(2):345-6. PubMed ID: 17448595
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment.
    Gambacorti-Passerini C; Piazza R; Tornaghi L; Pilotti S; Pogliani E
    J Natl Cancer Inst; 2004 Nov; 96(22):1723-4. PubMed ID: 15547187
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of somatostatin analogs in the management of prostate cancer.
    Sinisi AA; Rossi V; Prezioso D; Notaro A; Bellastella G; Panza N; Bellastella A; Pasquali D
    J Endocrinol Invest; 2003; 26(8 Suppl):120-4. PubMed ID: 15233227
    [No Abstract]   [Full Text] [Related]  

  • 12. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas.
    Li J; Tan H; Dong X; Xu Z; Shi C; Han X; Jiang H; Krissansen GW; Sun X
    Dig Liver Dis; 2007 Jun; 39(6):557-65. PubMed ID: 17374519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines.
    Riedel F; Götte K; Goessler U; Sadick H; Hörmann K
    Anticancer Res; 2004; 24(4):2179-83. PubMed ID: 15330158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking cancer with RNA interference moves toward the clinic.
    Hede K
    J Natl Cancer Inst; 2005 May; 97(9):626-8. PubMed ID: 15870429
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells.
    Valenti MT; Dalle Carbonare L; Bertoldo F; Donatelli L; Lo Cascio V
    Eur J Pharmacol; 2008 Feb; 580(1-2):36-42. PubMed ID: 18037402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.
    Stoss O; Werther M; Zielinski D; Middel P; Jost N; Rüschoff J; Henkel T; Albers P
    Prostate Cancer Prostatic Dis; 2008; 11(2):166-72. PubMed ID: 17646850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The future has already begun. Molecular oncology of prostatic carcinoma].
    Gschwend JE; Noldus J
    Urologe A; 2004 Jun; 43(6):645. PubMed ID: 15098091
    [No Abstract]   [Full Text] [Related]  

  • 18. Telomerase targeted anticancer bioactive prodrug by antisense-based approach.
    Kapoor N; Sharma AK; Dwivedi V; Kumar A; Pati U; Misra K
    Cancer Lett; 2007 Apr; 248(2):245-50. PubMed ID: 16950563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nonsteroidal anti-inflammatory drug NS398 regulates the RECK gene expression in the prostate carcinoma strain DU145].
    Xu ZY; Gao JP; Sun YH; Zhang ZY; Ge JP; Xu CL; Wang LH
    Zhonghua Nan Ke Xue; 2008 Apr; 14(4):303-6. PubMed ID: 18481419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
    Thomadaki H; Mavridis K; Talieri M; Scorilas A
    Thromb Haemost; 2009 Feb; 101(2):373-80. PubMed ID: 19190824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.